Royal Bank Of Canada Mi Nk Therapeutics, Inc. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.87 - $1.56 $31 - $56	36 Added 29.03%	160 $0
Q1 2024 Nov 05, 2024	SELL	$0.84 - $1.12 $30 - $40	-36 Reduced 22.5%	124 $0
Q1 2024 May 15, 2024	SELL	$0.84 - $1.12 $442 - $590	-527 Reduced 80.95%	124 $0
Q4 2023 Feb 14, 2024	BUY	$0.88 - $1.21 $1 - $2	2 Added 0.31%	651 $0
Q3 2023 Nov 14, 2023	BUY	$1.1 - $2.09 $122 - $231	111 Added 20.63%	649 $0
Q2 2023 Aug 14, 2023	BUY	$0.89 - $3.33 $381 - $1,428	429 Added 393.58%	538 $1,000
Q1 2023 May 15, 2023	SELL	$1.9 - $2.48 $224 - $292	-118 Reduced 51.98%	109 $0
Q4 2022 Feb 14, 2023	SELL	$1.89 - $3.16 $455 - $761	-241 Reduced 51.5%	227 $0
Q3 2022 Nov 14, 2022	BUY	$1.19 - $3.4 $556 - $1,591	468 New	468 $1,000
Q2 2022 Aug 15, 2022	SELL	$1.25 - $3.25 $155 - $403	-124 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.2 - $4.75 $794 - $1,714	-361 Reduced 74.43%	124 $0
Q4 2021 Feb 14, 2022	BUY	$4.12 - $20.03 $1,998 - $9,714	485 New	485 $2,000

848K

Ticker INKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,775,100
Market Cap $24.3M
Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.